Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core S&P 500 ETF (IVV) vs Stryker Corporation (SYK) Price & Performance

iShares Core S&P 500 ETFTrade
Stryker CorporationTrade

Price performance (Past 24H)

Key statistics

iShares Core S&P 500 ETF vs Stryker Corporation — how do they compare? iShares Core S&P 500 ETF trades at $777.04, while Stryker Corporation trades at $345.72 (market cap $133.54B). The key difference: Stryker Corporation pays a 1.01% dividend while iShares Core S&P 500 ETF pays none, and iShares Core S&P 500 ETF is trading nearer its 52-week high, Stryker Corporation nearer its low. Which is the better fit depends on your goals.

IVVSYK
Sector
Broad Market / FactorTechnology
52-Week High
$776.81$394.34
52-Week Low
$634.93$282.58
Market Cap
$133.54B
Enterprise Value
$145.01B
Dividend Yield
1.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core S&P 500 ETF

IVV, tracking the S&P 500, trades at $776.77, up 0.01% with a bullish technical signal from moving averages but overbought RSI readings. The ETF benefits from strong institutional interest, as First Bank & Trust increased its stake by 24.8% in Q2 2026 (SEC filing, August 11, 2026), while Financial Advisory Corp reduced holdings by 3.1%. Market sentiment is mixed amid record highs and inflation concerns, with JPMorgan raising its S&P 500 target to 8,000 (FXEmpire, August 10, 2026).

Outlook remains positive due to robust corporate earnings and AI-driven growth, but risks include high valuations and potential pullbacks. Investors should focus on long-term diversification benefits, with the dividend offering steady income. Key resistance is at $777, with support at $772.

Stryker Corporation

Stryker (SYK) trades at $345.86, up slightly by 0.01% today, with a bullish technical signal and strong analyst support. The company reported a Q2 2026 earnings beat with $3.69 EPS versus $3.49 expected, driven by 9% organic sales growth and recovery from a cyber incident. Fundamentals show robust profitability with a 14.43% net income margin and 16.51% ROE, though valuation ratios like a P/E of 36.08 are elevated.

Outlook remains positive with raised guidance and new product launches like Mako RPS expanding market reach. Key risks include execution challenges post-cyberattack and competitive pressures. The consensus price target of $379.44 implies ~10% upside, supported by 74% buy ratings from analysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Core S&P 500 ETF

IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.

Read more on IVV

About Stryker Corporation

Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.

Read more on SYK